ArticleProbiotics and antimicrobial proteins2026
Lactobacillus plantarum Attenuates Intestinal Inflammation and Prolongs Remission in Experimental Models of Crohn's Disease.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Crohn's disease (CD) is a chronic gastrointestinal disorder involving host genetics, environment, and gut microbiota, with microbial-based approaches holding high therapeutic potential. This study focused on the potential of Lactobacillus plantarum to attenuate intestinal inflammation in SAMP1/YitFc mouse models of colitis and ileitis. We tested the potential of L. plantarum to; (i) protect against the severity of dextran sodium sulfate (DSS)-induced colitis (acute flare model), (ii) prolong Dexamethasone (DEX)-induced remission in older SAMP mice with established ileitis (remission model), (iii) prevent/attenuate disease onset in young SAMP mice (preclinical model). Body weight, fecal myeloperoxidase (fMPO), gut permeability (fluorescein isothiocyanate (FITC)-dextran), colonoscopy, 3-D stereomicroscopy and histology of intestinal tissues were assessed. Administration of L. plantarum (Lac) significantly attenuated intestinal inflammation across multiple SAMP mouse models. In DSS-induced colitis, treatment improved clinical and histologic disease activity, evidenced by greater weight retention, preserved colon length, enhanced barrier integrity, and reduced fMPO and colonoscopy scores (Lac: 3.1 ± 0.8 vs. control: 5.3 ± 1.2, p = 0.02). In DEX-induced remission model, L. plantarum prolonged remission and reduced relapse severity, demonstrated by improved weight maintenance, decreased gut permeability and inflammatory burden, and lower histologic scores (Lac: 6.0 ± 2.1 vs. control; 9.6 ± 2.0, p = 0.03). Early-life intervention further mitigated spontaneous ileitis, with reductions in intestinal permeability, inflammatory activity, and macroscopic lesion severity (Lac: 0.6 ± 0.7 vs. control: 1.9 ± 0.6, p = 0.03). L. plantarum improved gut barrier integrity and attenuated intestinal inflammation in experimental colitis and chronic ileitis models of IBD.
Indexed as
Identifiers
42584533What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.